IRVINE, Calif.--(BUSINESS WIRE)--AcuFocus, Inc. (www.AcuFocus.com) today announced the commercial launch and availability of the KAMRA inlay and the AcuTarget™ system in eye care centers across Asia and Europe. As a revolutionary treatment option for near vision loss, or presbyopia, the KAMRA corneal inlay is designed to create a small aperture effect for the eye, allowing patients to see near and intermediate objects more clearly. The AcuTarget system is an exclusive and patented technology used to guide surgeons on proper surgical placement of the KAMRA inlay.
Presbyopia affects more than 1.5 billion people globally.1 Until now patients could only treat presbyopia or near vision loss with reading glasses, contact lenses or LASIK. However, these options come with compromise, such as significant loss of distance and intermediate vision. The KAMRA inlay offers patients a new alternative, which significantly reduces dependence on reading glasses while maintaining a full range of vision.
The availability of the KAMRA inlay comes soon after the premier launch event hosted by AcuFocus in Paris, France. At this event, the KARMA inlay and the AcuTarget system as well as clinical data supporting this complete solution were introduced to an exclusive group of the world’s most prestigious ophthalmologists and refractive surgeons. As a result, multiple eye care practices across Asia and Europe committed to offering the KAMRA inlay in their practices.
“The strong interest that we see from leading ophthalmic practices around the world underscores the potential of the KAMRA inlay to truly change the paradigm in presbyopia treatment,” said Mike Judy, chief commercialization officer at AcuFocus. “The KAMRA inlay and the AcuTarget system offer eye care professionals a proven, precise and predictable solution for presbyopia, virtually eliminating a patient’s need for reading glasses.”
At the recent annual European Society for Cataract and Refractive Surgeons (ESCRS) meeting in Paris, France, Dr. Günther Grabner, professor of ophthalmology at the Paracelsus University of Salzburg presented data on the three-year postoperative performance of the KAMRA inlay for the first time. At three years, patients with the KAMRA inlay reported significant improvement in both uncorrected near vision acuity (UNVA) and intermediate uncorrected visual acuity (UIVA) two key sight measurements. In fact, at three years 97 percent achieved J3 or better with a mean UNVA of J1 and 91 percent achieved UIVA of 20/32 or better. These results demonstrate that patients can view a computer screen, see numbers on their mobile phone and read the newspaper without glasses.
“This data underscore that the KAMRA inlay is safe and effective, delivering a full range of vision with minimal unwanted visual sensations, such as glare and halo,” said Dr. Grabner. “Backed by nearly ten years of research and development and with more than 2,000 patients now treated with the KAMRA inlay, it is evident that this product is an excellent surgical option for presbyopia patients.”
About the KAMRA Inlay and the AcuTarget System
The KAMRA inlay is an intra-corneal inlay designed to create a small aperture effect, allowing the eye to see near and intermediate objects more clearly. By applying the “depth-of-focus” principle commonly used in photography, the KAMRA inlay controls light transmission allowing only central rays to reach the retina through a fixed 1.6 mm aperture. The KAMRA inlay is placed under a LASIK-type flap using the AcuTarget System. The AcuTarget System is an exclusive and patented technology used to guide surgeons on proper surgical placement of the KAMRA inlay, ensuring precise, predictable and repeatable implantation for best outcomes and overall patient satisfaction.
The AcuTarget System was developed in conjunction with SMI (SensoMotoric Instrument), a world leader in computer vision application development with over 15 years of experience customizing eye tracking and alignment solutions for cataract and refractive surgery.
The KAMRA inlay received CE mark for use in the European Union in 2005 and is an investigational device under Investigational Device Exemption (IDE) in the United States.
To learn more about the KAMRA inlay and the AcuTarget System please visit www.KAMRA.com.
Presbyopia, a part of the normal aging process, reduces the ability of the eye to focus on near objects. This condition occurs when the crystalline lens of the eye loses its flexibility, making it difficult to focus on close objects. Presbyopia may seem to occur suddenly, but the actual loss of flexibility takes place over a number of years, usually becoming noticeable in the early to mid-40s. Presbyopia is not a disease and it cannot be prevented. Traditionally, most people with presbyopia use reading glasses to improve their near vision.
AcuFocus, Inc., a privately held company located in Irvine, California, is developing the KAMRA inlay for the treatment of near vision loss (presbyopia). For more information about AcuFocus please visit www.AcuFocus.com.
1 Adult vision: 41 to 60 years of age. American Optometric Association. http://www.aoa.org/x9453.xml. Accessed 23 September 2010.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6454835&lang=en